Online inquiry

IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2192MR)

This product GTTS-WQ2192MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL15RA gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243539.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3601
UniProt ID Q13261
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2192MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5346MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ6090MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ1065MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ7939MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ8805MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ2120MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ1276MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ4899MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW